Gyre Therapeutics, Inc. Common Stock
GYREGyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies targeting neurological and neurodegenerative disorders. Utilizing advanced drug delivery platforms, Gyre aims to address unmet medical needs through novel treatments that improve patient outcomes.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 12, 2023 | $0.24 | 2023-01-13 | 2023-01-05 |
| September 20, 2022 | $1.43 | 2022-09-21 | 2022-09-06 |
| August 19, 2015 | $0.57 | 2015-08-20 | 2015-08-14 |
Dividends Summary
- Consistent Payer: Gyre Therapeutics, Inc. Common Stock has rewarded shareholders with 3 dividend payments over the past 8 years.
- Total Returned Value: Investors who held GYRE shares during this period received a total of $2.24 per share in dividend income.
- Latest Payout: The most recent dividend of $0.24/share was paid 1283 days ago, on January 12, 2023.
- Dividend Growth: Since 2015, the dividend payout has decreased by 57.8%, from $0.57 to $0.24.
Company News
Gyre Therapeutics has completed its all-stock acquisition of Cullgen Inc. for approximately $300 million, creating a fully integrated biopharmaceutical company with U.S. and China operations. The combined entity will have a commercial-stage product (ETUARY® for lung fibrosis) and a robust pipeline focused on fibrosis and inflammatory diseases, i...
Gyre Therapeutics reported full-year 2025 revenue of $116.6 million, up 10% year-over-year, within guidance. The company achieved alignment with China's CDE on conditional approval pathway for Hydronidone with NDA submission expected in H1 2026. Gyre completed enrollment in a Phase 3 pirfenidone pneumoconiosis trial and announced an agreement to ...
Gyre Therapeutics reported Q3 2025 net income of $5.9 million, with quarterly revenue of $30.6 million, up 20% year-over-year. The company revised full-year revenue guidance to $115-118 million due to delayed product rollouts and procurement uncertainties.
Gyre Therapeutics will present positive Phase 3 clinical trial results for Hydronidone, a novel anti-fibrotic agent targeting liver fibrosis in chronic hepatitis B, at AASLD's The Liver Meeting® 2025 in Washington D.C.
Gyre Therapeutics announced the appointment of Dr. Dan Weng to its Board of Directors, bringing nearly four decades of clinical trial management experience. The company is focused on developing fibrosis treatments and has a prominent product in the Chinese market.
